Evaluation of monoclonal antibody-mediated anti-acute myeloid leukemia immunotherapy in a SCID/hu model.

[1]  E. Ball,et al.  Phase I clinical trial of serotherapy in patients with acute myeloid leukemia with an immunoglobulin M monoclonal antibody to CD15. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[2]  R. Gingrich,et al.  Improved outcome for high-risk acute myeloid leukemia patients using autologous bone marrow transplantation and monoclonal antibody-purged bone marrow. , 1994, Blood.

[3]  M. Caligiuri,et al.  A cell initiating human acute myeloid leukaemia after transplantation into SCID mice , 1994, Nature.

[4]  R. Ueda,et al.  Growth of human myeloid leukemias in the human marrow environment of SCID-hu mice. , 1993, Blood.

[5]  Robert B Sim.  Activators and inhibitors of Complement , 1993 .

[6]  P. Nowell,et al.  The severe combined immunodeficient (SCID) mouse as a model for human myeloid leukemias. , 1992, Oncogene.

[7]  C. Sawyers,et al.  Propagation of human blastic myeloid leukemias in the SCID mouse. , 1992, Blood.

[8]  J. Fisher,et al.  Initial trial of bispecific antibody-mediated immunotherapy of CD15-bearing tumors: cytotoxicity of human tumor cells using a bispecific antibody comprised of anti-CD15 (MoAb PM81) and anti-CD64/Fc gamma RI (MoAb 32). , 1992, Journal of hematotherapy.

[9]  I. Weissman,et al.  Growth of primary T-cell non-Hodgkin's lymphomata in SCID-hu mice: requirement for a human lymphoid microenvironment. , 1991, Blood.

[10]  J. Titley,et al.  Growth of primary human acute leukemia in severe combined immunodeficient mice. , 1991, Experimental hematology.

[11]  B. Lange,et al.  Homing and progression patterns of childhood acute lymphoblastic leukemias in severe combined immunodeficiency mice. , 1991, Blood.

[12]  R Berger,et al.  NB4, a maturation inducible cell line with t(15;17) marker isolated from a human acute promyelocytic leukemia (M3). , 1991, Blood.

[13]  J. Dick,et al.  A model of human acute lymphoblastic leukemia in immune-deficient SCID mice. , 1989, Science.

[14]  I. Weissman,et al.  The SCID-hu mouse: murine model for the analysis of human hematolymphoid differentiation and function. , 1988, Science.

[15]  C. Bloomfield,et al.  Use of surface marker analysis to predict outcome of adult acute myeloblastic leukemia. , 1986, Blood.

[16]  E. Ball,et al.  Monoclonal antibody-mediated cytotoxicity of human myeloid leukemia cells: an in vitro model for estimating efficiency and optimal conditions for cytolysis. , 1985, Blood.

[17]  J. Griffin,et al.  Heterogeneity of clonogenic cells in acute myeloblastic leukemia. , 1985, The Journal of clinical investigation.

[18]  R. Graziano,et al.  A unique antigen expressed on myeloid cells and acute leukemia blast cells defined by a monoclonal antibody. , 1983, Journal of immunology.

[19]  R. Graziano,et al.  Monoclonal antibodies to novel myeloid antigens reveal human neutrophil heterogeneity. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[20]  J. Pryjma,et al.  Prolonged C3 depletion by cobra venom factor in thymus-deprived mice and its implication for the role of C3 as an essential second signal for B-cell triggering. , 1975, Immunology.

[21]  R. H. Tew,et al.  In vitro detection of cytotoxic cellular immunity against tumor-specific antigens by a radioisotopic technique. , 1971, Proceedings of the National Academy of Sciences of the United States of America.